MedTrace Logo

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.

Conditions

  • Sialorrhoea

Interventions

DRUG

oxybutynin and clonidine oral solution treatment A

DRUG

oxybutynin and clonidine oral solution treatment B

DRUG

oxybutynin and clonidine oral solution treatment C

DRUG

oxybutynin and clonidine oral solution treatment D

Placebo

Sponsors & Collaborators

  • Orient Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Aaron L Ellenbogen, DO, MPH · QUEST Research Institute

  • Chi-Tai Chang, PhD · Orient Pharma Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01370811 on ClinicalTrials.gov